Genelabs Medical (Pvt) Ltd

What Genelabs Medical (Pvt) Ltd does

Genelabs Medical (Pvt) Ltd is a Sri Lanka–based genetic testing laboratory founded in 2018 by molecular geneticist Dr. Chandanamali Punchihewa, with headquarters and a state-of-the-art facility on Nawala Road. The company operates a national network of 15+ collection centers covering major Sri Lankan cities (Kandy, Galle, Jaffna, Badulla, Matale, Chilaw, Akkaraipattu, Tangalle, Polonnaruwa, and others), collecting samples that are processed at the central Nawala laboratory. Its core technology stack is built on ThermoFisher Scientific and Applied Biosystems instruments: the Genestudio S5 NGS system (Ion Torrent), Seqstudio capillary electrophoresis/Sanger sequencer, and Quantsudio S5 real-time PCR.

The product portfolio covers four disease areas: prenatal (NIPT — where Genelabs is the first in Sri Lanka — plus PGS and PGD for IVF couples), oncology (BRCA1/2, lung, colorectal/thyroid/prostate cancer mutation panels, AML/ALL/GIST/FGFR3 panels), hematology (HLA typing for transplantation, MPN, TP53, BCR-ABL, PML-RARA, translocation panels), and diabetes (MODY test launched in 2023). Extended service lines include Sanger sequencing, contract research, and a teaching/training program. The firm also extended into infectious-disease diagnostics during 2020, becoming the first non-hospital private lab authorized for COVID-19 PCR testing and the only private-sector lab in Sri Lanka performing SARS-CoV-2 variant sequencing.

The business is a fee-for-service testing laboratory: revenue accrues from one-time test charges per analysis (pricing is quote-based, not published), billed to hospitals, fertility clinics, individual patients, and academic/research customers. Genelabs is a founder-owned private limited company with no disclosed institutional investors, parent, or subsidiary; key partnership relationships are with ThermoFisher Scientific (equipment), the National Research Council (2021 PPP Research Grant), and the U.S. Embassy of Sri Lanka (2025 Bioinformatics workshop). Growth has been entirely bootstrapped through test revenue and non-dilutive grants, with recent capital deployment focused on facility expansion and product-line extension rather than geographic diversification beyond Sri Lanka.

Name

Genelabs Medical (Pvt) Ltd

Legal name

Genelabs Medical Private Limited

Website

https://genelabsmedical.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Genelabs Medical is Sri Lanka's premier genetic testing laboratory, founded in 2018, operating 15+ collection centers nationwide. It offers NIPT, oncology panels, hematology diagnostics, and the MODY diabetes test using NGS, Sanger, and PCR technologies to hospitals, fertility clinics, patients, and researchers.

Ownership category

akta.pro rank

Product category

Genetic Testing Laboratory Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Scientific Research and Development Services (5417)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro industry

PRIMARYHLAFAMAE

Molecular Diagnostics & Genomics Laboratories

Healthcare & Life Sciences/Healthcare Providers & Systems/Clinical Laboratories

SECONDARYHLAAALAA

Molecular Diagnostics (PCR/qPCR, NGS-based assays)

Healthcare & Life Sciences/Biotechnology & Biologics/Diagnostics (Biotech-related)

Keywords

• Genetic testing services
• Prenatal genetic screening
• Oncology mutation panels
• DNA paternity testing
• HLA typing laboratory

Headquarters

HQ city

Nawala

HQ country

Sri Lanka

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Genetic Testing Services: Laboratory testing services providing genetic analysis for clinical diagnosis including prenatal testing, cancer diagnostics, paternity testing, and HLA typing. Revenue is generated through individual test fees per analysis performed.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Genelabs Medical operates a genetic testing laboratory in Sri Lanka providing molecular diagnostics including Non-invasive Prenatal Testing (NIPT), pre-implantation genetic screening/diagnosis for IVF, oncology mutation panels (BRCA, lung, colorectal, thyroid, prostate, AML, GIST), HLA typing for organ transplantation, DNA paternity testing, and Sanger sequencing services. The company also offers contract research, academic collaborations, and teaching/training programs using NGS, Sanger sequencing, and real-time PCR platforms.

Product overview

Genelabs Medical is a genetic testing laboratory providing a comprehensive menu of genetic tests and services in Sri Lanka. The company offers Non-invasive Prenatal Testing (NIPT) as its flagship service, being the first in the country to perform this internationally recommended test. The product portfolio includes prenatal testing (NIPT, PGS, PGD), oncology testing panels (BRCA, cancer hotspot panel, lung cancer, colorectal cancer, thyroid cancer, prostate cancer, AML, ALL, GIST panels), hematology testing (HLA typing, MPN mutations, TP53, BCR-ABL, PML-RARA, ABL1, translocation panels), and diabetes testing (MODY). Extended services include Sanger sequencing, research & development support, and teaching/training programs. The company utilizes Next Generation Sequencing (NGS), Sanger sequencing, and PCR technologies.

Differentiator

Problem solved

Functional benefit

Products and services

• Non-invasive Prenatal Testing (NIPT)
• Pre-implantation Genetic Screening (PGS/PGT-A)
• Pre-implantation Genetic Diagnosis (PGD/PGT-M)
• BRCA 1 & 2 Panel
• DNA Paternity Testing
• Lung Cancer Mutation Panel
• RAS Extended Plus for Colorectal Cancer
• Thyroid Cancer Mutation Profile
• HLA Typing
• Cancer Hotspot Panel
• AML Mutation Panel
• GIST Mutation Panel
• Prostate Cancer Mutation Panel
• MODY (Maturity-Onset Diabetes of the Young) Test
• Sanger Sequencing Services
• Research & Development Services
• Teaching and Training Services
• ABL1 TKI Resistance Mutations

Quantifiable outcome

• NIPT test accuracy up to 99%
• +2 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• U.S. Embassy of Sri LankacoreStrategic or Co-development Partner · 1 January 2025Collaboration under the Embassy Science Fellow program for the Bioinformatics for Genomics Medicine 2025 workshop. Focused on strengthening bioinformatics knowledge and skills among genomics scientists in Sri Lanka. Workshop emphasized the importance of bioinformatics in modern clinical genetic testing.
• National Research CouncilcoreStrategic or Co-development Partner · 1 January 2021Awarded PPP (Public Private Partnership) Research Grant for development of a genetic test for diagnosis of Maturity Onset Diabetes of the Young (MODY).
• ThermoFisher ScientificcoreTechnology or IntegrationEquipment provider supplying Genestudio S5 NGS system, Seqstudio genetic analyzer, and Quantsudio S5 PCR machines. Ion Torrent technology has been referenced in over 4,000 publications.

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Centogene: Germany-based rare disease and genetic diagnostics laboratory providing NGS-based testing, prenatal screening and oncology panels — directly comparable specialty genetic lab with similar technology and menu.
• MedGenome: India-based genetic diagnostics and genomics research company offering NIPT, carrier screening, oncology panels and reproductive health testing — closely comparable in scope, technology and target customer to Genelabs but operating at much larger scale across South Asia.
• Mapmygenome: India-based personal genomics and molecular diagnostics company offering NIPT, carrier screening, cancer risk panels and paternity testing — very similar product mix to Genelabs with a regional South Asia focus.
• DNA Labs India: India-based genetic testing laboratory offering paternity, NIPT, cancer predisposition and prenatal panels — comparable in being a regional clinical lab focused on genetic diagnostics with NGS/PCR workflows.
• Strand Life Sciences: India-based genomics and clinical diagnostics provider spanning hereditary cancer, prenatal, reproductive health and hematology panels — directly comparable test menu and technology stack to Genelabs.

Broad incumbents

• Natera: US-based genetic testing company with leadership in cell-free DNA / NIPT and oncology minimal residual disease — directly comparable on NIPT and oncology liquid biopsy workflows that Genelabs is building in Sri Lanka.
• Myriad Genetics: US-based specialty genetic testing company with strong franchises in hereditary cancer (BRCA), prenatal screening and pharmacogenomics — directly overlapping Genelabs' BRCA, oncology and prenatal product lines but operating globally at much larger scale.
• Dr. Lal PathLabs: Large pan-India diagnostics chain with a growing genetics/molecular diagnostics vertical — comparable as a clinical lab operator serving healthcare providers and patients across South Asia, but much broader than Genelabs' focused genetic testing niche.
• Eurofins Genomics: Global genomics and life sciences services provider offering Sanger sequencing, NGS and contract research — overlaps with Genelabs' Sanger sequencing and R&D service offerings at vastly larger international scale.
• Revvity (formerly PerkinElmer): Global life sciences and diagnostics company offering reproductive health, newborn screening and clinical genomics solutions — comparable to Genelabs in NIPT/reproductive genetics space but as a broad, established multinational.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/Genelabsmedical
• LinkedInlinkedin.com/company/genelabs-medical-pvt-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genelabs Medical (Pvt) Ltd